29.04.2010 • NewsAkzoNobelHans Wijerscartel

Akzo Nobel CEO Takes Hard Line After Cartel Fines

Akzo Nobel CEO Hans Wijers said cartel-type practices were not acceptable and...
Akzo Nobel CEO Hans Wijers said cartel-type practices were not acceptable and it would represent the "end of career" for staff found to be engaging in such activities.

Dutch chemical group Akzo Nobel's chief executive took a hard line on Wednesday after recent European Commission cartel fines imposed on the firm, stressing that such practices were no longer acceptable.

Akzo Nobel was fined €40.6 million in November for belonging to a cartel that fixed prices for heat stabilizers, but escaped a fine in July because it blew the whistle on nine companies for forming a calcium carbide cartel.

Speaking at the company's annual shareholders meeting in Amsterdam, Akzo Nobel CEO Hans Wijers said cartel-type practices were not acceptable and it would represent the "end of career" for staff found to be engaging in such activities.

Akzo Nobel's Chief Financial Officer Keith Nichols said in February the company had booked a fourth-quarter charge roughly corresponding with the November-imposed cartel fine. The company has since said in its 2009 annual report that the fine imposed on Akzo Nobel last year related to the period prior to Akzo Nobel's reinforced competition law compliance programme introduced between 1999 and 2000.

It added that the fact it blew the whistle on another cartel demonstrated the effectiveness of its compliance programme.

Company

Logo:

AkzoNobel

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.